Sarcolipin is a novel direct regulator of the SERCA pump that decreases cardiac contractility, an effect that can be reversed by beta-adrenergic agonists.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for SLN-targeted modulation of contractility; leaves open relevance to human heart failure.
Babu et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: